Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Alcon examines conjunctivitis therapy

Alcon examines conjunctivitis therapy

6th July 2009

Alcon has begun clinical tests of a treatment for viral conjunctivitis.

The company is examining its partner NovaBay’s patented Aganocide compound NVC-422 for the medical condition – which is also known as pink eye – after the firms signed a licensing and research agreement.

Due to the product’s natural mechanism of action, Novabay – the business that developed the therapy to mimic the body’s natural defence system – believes the compounds are likely to have a minimal chance of generating microbial resistance.

Alcon’s senior vice-president of research and development and chief medical officer Dr Sabri Markabi explained the study is a critical step forward for the treatment of causes of the eye problem.

“Dual action against viral and bacterial conjunctivitis is important because when an infection is diagnosed it is difficult, time-consuming and expensive to determine the underlying cause of the infection and treat it properly,” he said.

Earlier this month, Alcon discontinued development of anecortave acetate for the reduction of intraocular pressure associated with glaucoma.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.